Drugs / H-1337
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06572397 | Sep → Oct 2024 | ocular hypertension, open-angle glaucoma | D. Western Therapeutics Institute, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03452033 | Mar → Aug 2018 | open-angle glaucoma | Allysta Pharmaceutical | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05913232 | Aug 2023 → Aug 2024 | ocular hypertension, open-angle glaucoma | D. Western Therapeutics Institute, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H-1337 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06572397 ↗ |
| Route | Topical | “H-1337 ophthalmic solution at 0.06%, 0.2%, and 0.6% or its vehicle twice daily unilaterally in the study eye” PMID 36055467 ↗ Aug 2022 |